{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"28"}],"units":"Participants"}],"description":"Response is Complete Remission (CR) + Partial Remission (PR) + Marrow CR = Complete Remission (CR) is \\</=5% myeloblasts with normal maturation of all cell lines\\* Persistent dysplasia will be noted, Peripheral blood; hemoglobin\\>/=11 g/dL, Platelets \\>/= 100x10\\^9/L ,Neutrophils \\>/=1.0 x 10\\^9/L, Blasts = 0%. Partial Remission (PR) is all CR criteria if abnormal before treatment except: Bone marrow blasts decreased by \\</=50% over pretreatment but still \\>5% Cellularity and morphology not relevant. Marrow CR is Bone marrow: \\</= 5% meyloblasts and decreased by \\>/= 50% over pretreatment† Peripheral blood: if HI responses, they will be noted in addition to marrow CR.","groups":[{"description":"Patients receive glutaminase inhibitor CB-839 PO BID on days 1-28 and azacitidine SC or IV over 10-40 minutes on days 1-7.\n\nAzacitidine: Given IV or SC\n\nGlutaminase Inhibitor CB-839: Given PO","id":"OG000","title":"Treatment (Glutaminase Inhibitor CB-839, Azacitidine)"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"Up to 5 years, 4 months","title":"Number of Participants With a Response","type":"PRIMARY","unitOfMeasure":"Participants"}